Sanofi SA Expected to Post Q2 2019 Earnings of $0.64 Per Share (NYSE:SNY)

Sanofi SA (NYSE:SNY) – Investment analysts at Jefferies Financial Group issued their Q2 2019 earnings estimates for shares of Sanofi in a note issued to investors on Wednesday, July 10th. Jefferies Financial Group analyst P. Welford forecasts that the company will post earnings per share of $0.64 for the quarter. Jefferies Financial Group also issued estimates for Sanofi’s Q3 2019 earnings at $1.13 EPS, Q4 2019 earnings at $0.70 EPS, FY2019 earnings at $3.29 EPS, FY2020 earnings at $3.62 EPS and FY2021 earnings at $3.94 EPS.

Sanofi (NYSE:SNY) last released its quarterly earnings data on Friday, April 26th. The company reported $0.81 EPS for the quarter, topping analysts’ consensus estimates of $0.74 by $0.07. Sanofi had a return on equity of 18.18% and a net margin of 12.20%. The firm had revenue of $8.39 billion for the quarter, compared to the consensus estimate of $8.34 billion. During the same quarter in the prior year, the company posted $1.28 earnings per share. The firm’s revenue was up 6.2% on a year-over-year basis.

Separately, TheStreet raised Sanofi from a “c+” rating to a “b-” rating in a research report on Friday, June 21st. Eight equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The company has a consensus rating of “Hold” and a consensus target price of $51.00.

Shares of SNY stock opened at $41.28 on Friday. Sanofi has a 12 month low of $40.19 and a 12 month high of $45.62. The company has a debt-to-equity ratio of 0.40, a quick ratio of 0.85 and a current ratio of 1.22. The company’s 50 day moving average is $42.80. The firm has a market capitalization of $103.05 billion, a P/E ratio of 13.19, a PEG ratio of 2.41 and a beta of 0.67.

Several large investors have recently made changes to their positions in SNY. Bank of New York Mellon Corp increased its stake in shares of Sanofi by 79.7% in the fourth quarter. Bank of New York Mellon Corp now owns 280,659 shares of the company’s stock valued at $12,184,000 after buying an additional 124,476 shares in the last quarter. Bessemer Group Inc. increased its position in Sanofi by 11.8% in the fourth quarter. Bessemer Group Inc. now owns 2,409 shares of the company’s stock worth $104,000 after purchasing an additional 255 shares during the period. Brown Advisory Inc. increased its position in Sanofi by 1.2% in the fourth quarter. Brown Advisory Inc. now owns 81,497 shares of the company’s stock worth $3,538,000 after purchasing an additional 955 shares during the period. Geode Capital Management LLC increased its position in Sanofi by 10.8% in the fourth quarter. Geode Capital Management LLC now owns 56,590 shares of the company’s stock worth $2,456,000 after purchasing an additional 5,525 shares during the period. Finally, BOKF NA increased its position in Sanofi by 30.4% in the fourth quarter. BOKF NA now owns 8,288 shares of the company’s stock worth $360,000 after purchasing an additional 1,932 shares during the period. Institutional investors own 7.04% of the company’s stock.

About Sanofi

Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.

See Also: Why do companies issue stock splits?

Earnings History and Estimates for Sanofi (NYSE:SNY)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with's FREE daily email newsletter.